Email this article A herd immunity to measles and rubella viruses in the population of the Republic of Serbia
- Authors: Bichurina M.A.1, Filipovic-Vignjevic S.2, Antipova A.Y.1, Bancevic M.2, Lavrentieva I.N.1
-
Affiliations:
- St. Petersburg Pasteur Institute
- Institute of Virology, Vaccines and Sera Torlak
- Issue: Vol 11, No 1 (2021)
- Pages: 171-176
- Section: SHORT COMMUNICATIONS
- URL: https://iimmun.ru/iimm/article/view/1496
- DOI: https://doi.org/10.15789/2220-7619-AHI-1496
- ID: 1496
Cite item
Full Text
Abstract
According to the WHO Strategic Plan, measles should be eradicated in 2020 in the five WHO Regions including European Region. However, large measles outbreaks are being periodically registered in diverse European countries. In the Republic of Serbia (SRB), 5,076 measles cases were detected in 2018, among which 15 cases were fatal.
Aim of the study was to examine herd immunity to measles and rubella viruses in the population of the Republic of Serbia.
Materials and methods. Blood serum samples obtained in 2018 and 2019 from conditionally healthy residents of the Republic of Serbia were tested for the presence of IgG antibodies to measles and rubella viruses in five age groups: I — children from 2 to 6 years old, II — children from 8 to 14 years old, III — 15 to 24 years old, IV — 25 to 49 years old and V — over 50 years old. A total of 1000 samples were obtained, 200 sera in each group. Enzygnost® Anti-Measles virus/IgG and Enzygnost® Anti-Rubella virus/IgG ELISA test systems (Siemens Healthcare Diagnostics Products GmbH, Germany) were used according to the manufacturer's instructions.
Results. Overall, around 23.0% and 33.7% of the surveyed persons had no or low level of anti-measles IgG antibody (≥ 275.0 — ≤ 1000.0 IU/1). In age group I, 60% children contained no or “low” anti-measles antibodies titer (29.5% and 30.5%, respectively). In addition, low antibody titer level was mainly detected in individuals from age group II and III (p < 0.05). A third of children under 8—14 contained high IgG-antibodies titer against measles (> 3000.0 IU/l) that might serve as an evidence that such subjects recently recovered after measles. Similar results were obtained for IgG antibodies to rubella in the same age groups.
Discussion. The study results evidence about altered routine immunization against measles and rubella in children aged 12—15 months (first vaccination) and those at age of 6—7 years (revaccination) with MMR vaccine. The data obtained correlate with official data on coverage with measles and rubella vaccines in the Republic of Serbia.
Keywords
About the authors
M. A. Bichurina
St. Petersburg Pasteur Institute
Email: poliospb@nr3854.spb.edu
ORCID iD: 0000-0001-5184-0315
PhD, MD (Medicine), Head of the Virological Laboratory of Measles and Rubella Elimination.
St. Petersburg
Russian FederationS. Filipovic-Vignjevic
Institute of Virology, Vaccines and Sera Torlak
Email: sfilipovic@torlak.rs
ORCID iD: 0000-0002-1373-6872
Filipovic-Vignjevic S.B., Doctor, Assistant Director for Diagnostics and Scientific Development, Head of National Reference Laboratory for Influenza.
Belgrade
A. Yu. Antipova
St. Petersburg Pasteur Institute
Author for correspondence.
Email: anti130403@mail.ru
ORCID iD: 0000-0002-7763-535X
Anastasia Yu. Antipova - PhD (Biology), Senior Researcher, Laboratory of Experimental Virology.
197101, St. Petersburg, Mira str., 14, Phone: +7 (812) 232-94-11
Russian FederationM. Bancevic
Institute of Virology, Vaccines and Sera Torlak
Email: mbancevic@torlak.rs
ORCID iD: 0000-0003-2364-9980
PhD, MD (Medicine), Specialist in Medical Microbiology, Head of National Reference Laboratory for Measles and Rubella.
BelgradeI. N. Lavrentieva
St. Petersburg Pasteur Institute
Email: pasteur.lawr@mail.ru
ORCID iD: 0000-0002-2188-6547
PhD, MD (Medicine), Head of the Laboratory of Experimental Virology.
St. Petersburg
Russian FederationReferences
- Бичурина М.А., Тимофеева Е.В., Железнова Н.В., Игнатьева Н.А., Шульга С.В., Лялина Л.В., Дегтярев О.В. Вспышка кори в детской больнице Санкт-Петербурга в 2012 году // Журнал инфектологии. 2013. Т. 5, № 2. С. 96-102.
- Результаты сертификации территорий СЗФО на отсутствие циркуляции эндемичного вируса кори: аналитический обзор. СПб.: ФБУН НИИЭМ им. Пастера, 2012. 60 с.
- Ситуация по кори на территориях Северо-Западного федерального округа и трудности диагностики при спорадическом уровне заболеваемости: аналитический обзор. СПб.: ФБУН НИИЭМ им. Пастера, 2017. 76 с.
- Совершенствование эпидемиологического надзора за корью в Северо-Западном федеральном округе России на этапе ликвидации инфекции: аналитический обзор. СПб.: ФБУН НИИЭМ им. Пастера, 2008. 52 с.
- Actual epidemiological situation of measles in Serbia. Belgrade: Institute of Public Health of Serbia, 2019. URL: http://www.batut.org.rs/index.php?content=1629 (25.12.2019)
- Andrianou X.D., Del Manso M., Bella A., Vescio M.F., Baggieri M., Rota M.C., Pezzotti P., Filia A. Spatiotemporal distribution and determinants of measles incidence during a large outbreak, Italy, September 2016 to July 2018. Eurosurveillance, 2019, vol. 24, no. 17: 1800679. doi: 10.2807/1560-7917.ES.2019.24.17.1800679
- CDC. Increased Transmission and Outbreaks of Measles — European Region, 2011. MMWR, 2011, vol. 60, no. 47, pp. 1605—1610.
- Nedeljkovic J., Rakic-Adrovic S., Tasic G., Kovacevic-Jovanovic V., Loncarevic G., Hubschen J.M., Muller C.P. Resurgence of measles in Serbia 2010—2011 highlights the need for supplementary immunization activities. Epidemiol. Infect., 2016, vol. 144, no. 5, pp.1121-1128. doi: 10.1017/S0950268815002277
- Orenstein W.A., Hinman A., Nkowane B., Olive J.M., Reingold A. Measles and rubella global strategic plan 2012—2020 midterm review. Vaccine, 2018, vol. 36, no. 1: A1-A34. doi: 10.1016/j.vaccine.2017.09.026
- Ristic M., Milosevic V., Medic S., Djekic Malbasa J., Rajcevic S., Boban J., Petrovic V. Seroepidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia. PLoS One, 2019, vol. 14, no. 5: e0216219. doi: 10.1371/journal.pone.0216219
- WHO. Eliminating measles and rubella and preventing congenital rubella infection: WHO European Region strategic plan 2005— 2010. Copenhagen: WHO, 2005. 34 p.
- WHO. Global Vaccine Action Plan 2011-2020. Geneva: WHO, 2013. 77 p.
- WHO. Manual for the laboratory diagnosis of measles and rubella virus infection. 2nd ed. Geneva: WHO, 2006. 22 p.
- WHO. Measles — European Region. 2019. URL: https://www.who.int/csr/don/06-may-2019-measles-euro/en (25.12.2019)
- Zimmerman L.A., Muscat M., Singh S., Ben Mamou M., Jankovic D., Datta S., Alexander J.P., Goodson J.L., O’Connor P. Progress toward measles elimination — European Region, 2009-2018. MMWR, 2019, vol. 68, no. 17, pp. 396-401.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).